1 citations
,
July 2024 in “Journal of Cosmetic Dermatology” This study found that 63.4% of androgenetic alopecia patients showed clinical improvement after 6 months of low-dose oral minoxidil, with patients having low sulfotransferase activity in hair follicles responding more favorably than those with high enzyme activity.
March 2024 in “Dermatology and therapy (Internet)” This study identified eight genetic markers associated with androgenetic alopecia, suggesting that these SNPs could influence individualized therapeutic responses and highlight the need for personalized treatment strategies.
September 2023 in “Nature Communications” In this study, the researchers found that rare genetic variants make a minor contribution to male-pattern hair loss risk, identifying five significant gene associations, including novel genes, and noting a shared basis with monogenic hair loss disorders.
September 2023 in “Medicina-lithuania” In this study, DNA analysis of patients with androgenetic alopecia and alopecia areata indicated potential differences in treatment response based on genetic makeup across Romanian and Brazilian populations, notably involving genes like GR-alpha and SULT1A1, which may guide personalized treatment strategies.
2 citations
,
August 2023 in “Journal of Cutaneous Medicine and Surgery” This study concluded that platelet-rich plasma is effective and safe for increasing hair density in androgenetic alopecia, showing significant improvement compared to placebo at 3 and 6 months.
June 2023 in “Frontiers in Medicine” This study identified core genes and pathways involved in androgenetic alopecia, finding that genes related to hair follicle development are down-regulated, while those linked to immune responses are up-regulated, highlighting potential therapeutic targets.
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
May 2023 in “Clinical, Cosmetic and Investigational Dermatology” This review examines the efficacy of various novel treatments for androgenetic alopecia, including oral minoxidil and platelet-rich plasma, suggesting potential benefits but emphasizing the need for further high-quality clinical trials to thoroughly evaluate their effectiveness.
4 citations
,
January 2023 in “Frontiers in Immunology” In this Mendelian randomization study, shortened leukocyte telomere length was associated with an increased risk of androgenetic alopecia, but no causal relationship was found with alopecia areata.
January 2023 in “Frontiers in Medicine” This study found that ALRV5XR showed the highest efficacy for terminal hair regrowth in both men and women with androgenetic alopecia, with less treatment resistance compared to other therapies.
This review discusses the role of the Wnt/β-catenin pathway in hair follicle development and how natural products that activate this signaling could be used to treat hair loss, but it reports no new experimental results.
November 2022 in “Molecular Pharmaceutics” This study found that intradermal injection of a cell-penetrating, AR-targeting asiRNA promoted hair growth and reduced androgen receptor expression in mouse models of androgenetic alopecia, suggesting its therapeutic potential.
3 citations
,
November 2022 in “European Journal of Human Genetics” This study developed new genetic prediction models for male pattern baldness with improved accuracy by utilizing a large set of markers and independent datasets, making them the most reliable available for this trait.
October 2022 in “The Korean Journal of Physiology and Pharmacology” This review discusses the roles of prostaglandins in hair loss and highlights their potential as targets for new alopecia treatments, but reports no new clinical findings.
August 2022 in “Journal of Cosmetic Dermatology” This study found that 1% topical cetirizine may be more effective than a placebo in treating androgenetic alopecia but appears less effective than minoxidil for hair density, though potentially longer-lasting; however, more well-designed RCTs are needed to confirm these findings.
1 citations
,
July 2022 in “JEADV Clinical Practice” This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.
This review compiles existing information on the pathogenesis of androgenetic alopecia, highlighting its genetic, hormonal, and environmental factors, but reports no new clinical findings.
1 citations
,
April 2022 in “Journal of Cosmetic Dermatology” This review highlights that androgenetic alopecia significantly impacts psychological well-being and quality of life, emphasizing the need for integrated psychological support alongside dermatological treatment.
3 citations
,
January 2022 in “Scientific Reports” This study found that SAMiRNA-AR68, a nanomedicine targeting androgen receptor mRNA, increased hair counts in androgenetic alopecia patients with no observed side effects.
17 citations
,
November 2021 in “Journal of Cosmetic Dermatology” This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.
30 citations
,
October 2020 in “Nature Communications” This study provides the first crystal structure of the human SRD5A2 enzyme, revealing key insights into its function and inhibition which may aid future drug development.
86 citations
,
July 2020 in “International Journal of Molecular Sciences” This review discusses the role of Wnt/β-catenin signaling in hair follicle regeneration and highlights recent progress in developing hair loss treatments targeting this pathway, but reports no new clinical results.
19 citations
,
April 2020 in “Dermatologic Therapy” This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.
117 citations
,
August 2019 in “Drug Design Development and Therapy” This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.
8 citations
,
June 2019 in “Scientific Reports” This study found that the retinoid receptor and PPAR pathway are involved in hair follicle miniaturization in androgenetic alopecia, alongside androgen receptors.
6 citations
,
January 2019 in “Biochemical and Biophysical Research Communications” This study suggests that Sox13, although dispensable for epidermal development, serves as a marker for early hair follicle development in Sox13-LacZ knock-in mice.
58 citations
,
December 2018 in “Nature Communications” This study found that male pattern baldness in European males is strongly heritable and associated with genetic markers linked to earlier puberty, bone density, and pancreatic function.
24 citations
,
January 2018 in “Indian Journal of Dermatology, Venereology and Leprology” This review discusses advances in molecular biology and genetics related to androgenetic alopecia and reports no new clinical results.
145 citations
,
November 2017 in “Journal of The European Academy of Dermatology and Venereology” This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.
57 citations
,
November 2017 in “Nature Communications” This genome-wide association study identified 71 genetic loci linked to male pattern baldness, with 30 novel loci, explaining 38% of the risk and suggesting shared pathways with lifespan and cancer traits.
99 citations
,
July 2017 in “Clinical Reviews in Allergy & Immunology” This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.
178 citations
,
April 2017 in “Journal of The American Academy of Dermatology” This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.
153 citations
,
March 2017 in “Endocrine” This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.
64 citations
,
March 2017 in “Journal of Cosmetic Dermatology” This meta-analysis suggests that local injection of platelet-rich plasma for androgenic alopecia is associated with an increased number of hairs and some increase in hair thickness, though larger studies are needed for confirmation.
64 citations
,
March 2017 in “Nature communications” This study identified 63 genetic loci associated with male-pattern baldness, uncovering genes and pathways that may help develop treatments and suggesting its connection to other human conditions.
133 citations
,
February 2017 in “PLoS Genetics” In this study, researchers used genetic data from over 52,000 men to identify over 250 genetic loci associated with severe hair loss and developed a predictive algorithm for determining hair loss risk.
37 citations
,
February 2017 in “Anais Brasileiros De Dermatologia” In this study, researchers found that the prevalence of androgenetic alopecia was higher in their sample compared to other studies in Asian and Caucasian populations, and it was linked with age-related severity.
57 citations
,
February 2014 in “Experimental Dermatology” This review discusses the role of Prostaglandin D2 and its synthase in androgenetic alopecia but reports no new clinical findings, suggesting pathways for future therapeutic development.
74 citations
,
January 2013 in “Journal of Investigative Dermatology” Four genetic risk spots found for hair loss, with WNT signaling involved and a link to curly hair.
87 citations
,
May 2012 in “PLOS Genetics” This study found that early-onset androgenetic alopecia in individuals of European ancestry is significantly associated with increased odds of Parkinson's disease and is influenced by specific genetic loci, including some linked to reduced fertility.
205 citations
,
March 2012 in “Science Translational Medicine” PGD2 stops hair growth and is higher in bald men with AGA.
22 citations
,
March 2012 in “Molecular Medicine Reports” This study found that DHT treatment led to reduced cell growth, increased cell death, cell cycle arrest, ROS production, and senescence in normal human dermal papilla cells, potentially mediated by altered miRNA expression.
51 citations
,
November 2011 in “British Journal of Dermatology” This study suggests that the HDAC9 gene is a third susceptibility gene for male-pattern baldness, with significant associations found in both German and Australian samples.
41 citations
,
October 2011 in “Clinical and Experimental Dermatology” This meta-analysis suggests that the G allele of AR StuI polymorphism might be a potential risk factor for AGA, particularly in white populations.
199 citations
,
April 2010 in “Nature” A gene called APCDD1, which controls hair growth, is found to be faulty in a type of hair loss called hereditary hypotrichosis simplex.
82 citations
,
April 2008 in “Journal of Investigative Dermatology” EDA2R gene linked to hair loss.
62 citations
,
March 2008 in “American Journal of Human Genetics” This study located a potential genetic link for androgenetic alopecia on chromosome 3q26, marking an early step in identifying new susceptibility genes for male pattern baldness.
57 citations
,
November 2006 in “International Journal of Cancer” This study found that the SRD5A2 A49T A variant is associated with an increased risk of prostate cancer, lower circulating 3α‐diolG levels, and a decreased risk of baldness.
195 citations
,
June 2005 in “American Journal of Human Genetics” Genetic variation in the androgen receptor gene mainly causes early-onset hair loss, with maternal inheritance playing a key role.
34 citations
,
June 2005 in “Developmental dynamics” This study found that Runx3 deficiency in mice affects hair type and shape, suggesting it may regulate hair formation through interactions between dermal and epidermal layers.
10 citations
,
March 2004 in “Journal of the American Academy of Dermatology” The 5% minoxidil solution effectively treated hair loss with good tolerability.
397 citations
,
February 2004 in “British Journal of Dermatology” This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.
229 citations
,
August 2002 in “Experimental Gerontology” This paper discusses key mechanisms of androgen metabolism in androgenetic alopecia and reports the effectiveness of treatments like oral finasteride and topical minoxidil, highlighting the limited success rate due to factors like follicular inflammation.
581 citations
,
October 1998 in “Journal of The American Academy of Dermatology” In male pattern hair loss, this study found that finasteride 1 mg daily significantly slowed hair loss and increased hair growth over two years compared to placebo.
169 citations
,
June 1998 in “Journal of Investigative Dermatology” This study found no significant genetic association between the 5α-reductase enzyme genes and male pattern baldness, suggesting a polygenic etiology rather than simple inheritance.
